Expert Insights for Health Science Companies
As a global leader in health science M&A, recapitalization, and growth financing strategies, Crosstree has led 100+ transactions for companies at the center of this fast-moving industry.
The Prism Doctrine
January 22, 2020
Tomorrow’s ecosystem must allow for more specialized, complex treatments and patient journeys, which will be tailored to each therapy in the case of stratified medicine, and to each patient with personalized medicine.Read Research
We were impressed with the intensity and thoroughness of Crosstree’s preparation. Their team worked tirelessly on analytics and positioning, ultimately giving us the flexibility to efficiently navigate various strategic options involving our business and each of its two divisions. I wouldn’t think twice about using Crosstree again.
Crosstree did an exceptional job with our process. We benefited greatly from their industry knowledge, expansive network, deal expertise and just plain hard work. Most importantly, their bankers demonstrated sterling integrity and always gave us sound advice that resulted in an excellent outcome, despite numerous twists and turns along the way.
Crosstree’s specific knowledge of our market segment allowed them to precisely target potential buyers. Further, Crosstree guided management to the right “value drivers” for each potential buyer, optimally tuning our various presentations, and ultimately driving enhanced valuations during the auction process.